Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 10;41(20):3576-3579.
doi: 10.1200/JCO.23.00323. Epub 2023 Mar 22.

The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer

Hannah D McManus  1 , Andrew J Armstrong  1
Affiliations
Editorial

The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer

Hannah D McManus et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Andrew J. Armstrong

Consulting or Advisory Role: Bayer (less than $5,000 USD in a single calendar year), Pfizer ($5,000 USD or above in a single calendar year), Astellas Scientific and Medical Affairs, Inc ($5,000 USD or above in a single calendar year), AstraZeneca ($5,000 USD or above in a single calendar year), Merck (less than $5,000 USD in a single calendar year), Bristol Myers Squibb (less than $5,000 USD in a single calendar year), Janssen ($5,000 USD or above in a single calendar year), FORMA Therapeutics ($5,000 USD or above in a single calendar year), Novartis ($5,000 USD or above in a single calendar year), Exelixis ($5,000 USD or above in a single calendar year), Myovant Sciences ($5,000 USD or above in a single calendar year), GoodRx ($5,000 USD or above in a single calendar year), Epic Sciences ($5,000 USD or above in a single calendar year), IDEAYA Biosciences ($5,000 USD or above in a single calendar year)

Research Funding: Dendreon (Inst), Bayer (Inst), Pfizer (Inst), Novartis (Inst), Janssen Oncology (Inst), Astellas Pharma (Inst), Gilead Sciences (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Merck (Inst), AstraZeneca (Inst), BeiGene (Inst), Amgen (Inst), FORMA Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property: Circulating tumor cell novel capture technology (Inst)

Travel, Accommodations, Expenses: Astellas Scientific and Medical Affairs, Inc

No other potential conflicts of interest were reported.

Andrew J. Armstrong

Consulting or Advisory Role: Bayer (<$5,000 USD in a single calendar year), Pfizer ($5,000 USD or above in a single calendar year), Astellas Scientific and Medical Affairs, Inc ($5,000 USD or above in a single calendar year), AstraZeneca ($5,000 USD or above in a single calendar year), Merck (<$5,000 USD in a single calendar year), Bristol Myers Squibb (<$5,000 USD in a single calendar year), Janssen ($5,000 USD or above in a single calendar year), FORMA Therapeutics ($5,000 USD or above in a single calendar year), Novartis ($5,000 USD or above in a single calendar year), Exelixis ($5,000 USD or above in a single calendar year), Myovant Sciences ($5,000 USD or above in a single calendar year), GoodRx ($5,000 USD or above in a single calendar year), Epic Sciences ($5,000 USD or above in a single calendar year), IDEAYA Biosciences ($5,000 USD or above in a single calendar year)

Research Funding: Dendreon (Inst), Bayer (Inst), Pfizer (Inst), Novartis (Inst), Janssen Oncology (Inst), Astellas Pharma (Inst), Gilead Sciences (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Merck (Inst), AstraZeneca (Inst), BeiGene (Inst), Amgen (Inst), FORMA Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property: Circulating tumor cell novel capture technology (Inst)

Travel, Accommodations, Expenses: Astellas Scientific and Medical Affairs, Inc

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Proposed treatment approach for mHSPC on the basis of disease volume (high-volume v low-volume) and timing of metastatic disease development (synchronous/de novo v metachronous/relapsed). High-volume disease is defined as visceral metastases and/or ≥4 bone metastases with at least one outside of the vertebral column and pelvis on the basis of CHAARTED criteria. De novo mHSPC is defined as metastatic disease at the time of initial prostate cancer diagnosis. Relapsed/metachronous mHSPC is defined as metastatic disease identified after initial diagnosis and treatment for localized prostate cancer. Assessments are made using conventional imaging (computed tomography and bone scan). In all settings, a clinical trial should be considered to further evaluate optimal treatment strategies and improve outcomes. ADT, androgen-deprivation therapy; ARSI, androgen receptor signaling inhibitor; mHSPC, metastatic hormone–sensitive prostate cancer.
See this image and copyright information in PMC

Comment on

References

    1. Coiffier B, Lepage E, Brière J, et al. : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 - PubMed
    1. Williams SD, Birch R, Einhorn LH, et al. : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987 - PubMed
    1. Armstrong AJ, Azad AA, Iguchi T, et al. : Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40:1616-1622, 2022 - PMC - PubMed
    1. Chi KN, Chowdhury S, Bjartell A, et al. : Apalutamide in patients with metastatic castration sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294-2303, 2021 - PubMed
    1. Davis ID, Martin AJ, Stockler MR, et al. : Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121-131, 2019 - PubMed